Borough Park
1428 36th Street
Suite 107
Brooklyn NY 1121

Manhasset
333 East Shore Road
Suite 201
Manhasset, NY 11030 Rockville Centre
165 North Village Avenue
Suite 133
Rockville Center, NY 11570

Manhattan
57W 57Street
Suite 601
New York, NY 10019 Crown Heights
555 Lefferts Avenue
Brooklyn, NY 11225 Elmsford/Terrytown
555 Taxter Road
3rd Floor
Elmsford, NY 10523





Manhattan
225 E 70th Street
Suite 1E
New York, NY 10021

Scarsdale

495 Central Park Avenue
Suite 205
Scarsdale, NY 10583 Holbrook/Ronkonkoma
233 Union Ave
Suite 207
Holbrook, NY 11741

Queens
64-05 Yellowstone Blvd
CF104
Forest Hills, NY 11375

Manhattan 225 East 70th Street New York, NY 10021
5 Towns 141 Washington Avenue Cedarhurst, NY 11559

Long Beach
917 Beech Street
Long Beach, NY 11561

Riverhead
1228 E Main Street
Suite A
Riverhead, NY 11901

Provider Order Form

PATIENT INFORMATION				
Name:		DOB:		
Allergies:		Date of Referral:		
ICD-10 code (required):	ICD -10) description:		
□ NKDA Allergies:		Weight lbs/kg:		
Patient Status: New to Therapy Continue REFERRAL STATUS: New Prescription	□ Order Renewal □ [ue Date (if applicable):		
Referral Coordinator Name:	Referral	Coordinator Email:		
Ordering Provider:	Provide	r NPI:		
Referring Practice Name:	Phone:	Fax:		
Practice Address:	City:	State: Zip Code:		
NUBCINC		THERADY ADMINISTRATION		
Provide nursing care per IVX Nursing Procedures, including reaction management and post-procedure observation NOTE: IVX Adverse Reaction Management Protocol available for review at www.ivxhealth.com/forms (version 09.07.2021) PREN-MEDICATION ORDERS □ acetaminophen (Tylenol) □500mg / □650mg / □1000mg PO cetirizine (Zyrtec) 10mg PO □ loratadine (Claritin) 10mg PO □ diphenhydramine (Benadryl) □ 25mg / □50mg □PO / □IV methylprednisolone (Solu-Medrol) □40mg / □125mg IV □ Other: □ Dose: □ Route: □ Frequency: □ Route: □ Frequency: □ SPECIAL INSTRUCTIONS Closely observe patients for signs and symptoms of hypersensitivity including monitoring of blood pressure and pulse during and after Feraheme administration for at least 30 minutes and until clinically stable following completion of each infusion. Cobserve for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of each administration.*Monitor patients for signs and symptoms of hypersensitivity during and after Venofer administration for at least 30 minutes and until clinically during and after Venofer administration for at least 30 minutes and until clinically during and after Venofer administration for at least 30 minutes and until clinically during and after Venofer administration for at least 30 minutes and until clinically during and after Venofer administration for at least 30 minutes and until clinically during and after Venofer administration for at least 30 minutes and until clinically stable following completion of each administration.*		THERAPY ADMINISTRATION □ Ferumoxytol (Feraheme) intravenous infusion • Dose & Frequency: ☑initial 510mg infusion followed by a second 510mg infusion 3-8 days later • Dilutén 50 - 200ml 0.9% sodium chloride or 5% dextrose solution (final concentration 2mg - 8mg per ml) • Infuse over at least 15 minutes • No refills □ Other □ Ferriccarboxymaltose (Injectafer) intravenous infusion • Dose & Frequency:□Patients > 50kg: Two 750mg doses, 7 days apart / □Patients < 50kg: Two 15mg/kg doses, 7 days apart • Dilutén no more than 250ml 0.9% sodium chloride • Infuse over at least 15 minutes • No refills □ Other □ Iron sucrose(Venofer) intravenous infusion • Dose: • □ 100mg in 100ml 0.9% sodium chloride over 30 minutes □ 200mg in 100ml 0.9% sodium chloride over 30 minutes □ 300mg in 250ml 0.9% sodium chloride over 1.5 hours • □ 400mg in 250ml 0.9% sodium chloride over 2.5 hours • □ 400mg in 250ml 0.9% sodium chloride over 2.5 hours • □ 400mg in 250ml 0.9% sodium chloride over 2.5 hours • □ Frequency: □ Once □ Every 2- 3 days x □ doses □ Daily x □ doses □ Weekly x □ doses □ Daily x □ doses □ Other: □ Flush with 0.9% sodium chloride at the completion of infusion □ Patient required to stay for 30 - min observation period Total doses: □ 1 yr □ Other		
Provider Name (Print)	Provider Signature	Date		
ORDERING PROVIDER	-			
Signature X		Date		
Provider	Pho	one Fax		